NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial - Trial NCT06342037
Access comprehensive clinical trial information for NCT06342037 through Pure Global AI's free database. This Phase 2 trial is sponsored by The Netherlands Cancer Institute and is currently Not yet recruiting. The study focuses on Metastatic Breast Cancer. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
The Netherlands Cancer Institute
Timeline & Enrollment
Phase 2
May 15, 2024
Apr 01, 2030
Primary Outcome
PFS-12,Incidence of adverse events
Summary
This is a single center, non-blinded, multi-cohort, non-comparative phase II trial to study
 the safety and efficacy of tiragolumab with atezolizumab and/or ipilimumab in advanced
 triple-negative breast cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06342037
Non-Device Trial